Chemistry:4'-Methyl-α-pyrrolidinohexiophenone
 | |
| Clinical data | |
|---|---|
| Other names | MPHP |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C17H25NO |
| Molar mass | 259.393 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
4'-Methyl-α-pyrrolidinohexiophenone (MPHP) is a stimulant compound which has been reported as a novel designer drug.[1][2][3] It is closely related to pyrovalerone, being simply its chain-lengthened homologue. In the pyrrolidinophenone series, stimulant activity is maintained so long as the positions of the aryl, ketone and pyrrolidinyl groups are held constant, while the alkyl backbone can be varied anywhere between three and as many as seven carbons,[4] with highest potency usually seen with the pentyl or isohexyl backbone, and a variety of substituents are tolerated on the aromatic ring.[5]
In 2010 a group of researchers from the Institute of Forensic Medicine, University Hospital Jena, Germany concluded that MPHP can lead to serious poisoning with toxic liver damage and rhabdomyolysis.[6]
Legality
In the United States, MPHP is a Schedule I Controlled Substance.[7] Sweden's public health agency suggested to classify MPHP as narcotic on June 1, 2015.[8]
See also
References
- ↑ "New designer drug 4'-methyl-alpha-pyrrolidinohexanophenone: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 789 (1): 79–91. June 2003. doi:10.1016/S1570-0232(03)00043-6. PMID 12726846.
- ↑ "Biotechnological synthesis of the designer drug metabolite 4'-hydroxymethyl-alpha-pyrrolidinohexanophenone in fission yeast heterologously expressing human cytochrome P450 2D6--a versatile alternative to multistep chemical synthesis". Journal of Analytical Toxicology 33 (4): 190–7. May 2009. doi:10.1093/jat/33.4.190. PMID 19470220.
- ↑ "Acute poisoning involving the pyrrolidinophenone-type designer drug 4'-methyl-alpha-pyrrolidinohexanophenone (MPHP)". Forensic Science International 208 (1–3): e20-5. May 2011. doi:10.1016/j.forsciint.2011.02.026. PMID 21444164.
- ↑ "α-substituted-ketones and processes for their preparation." GB patent 1149366
- ↑ "1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors". Journal of Medicinal Chemistry 49 (4): 1420–32. February 2006. doi:10.1021/jm050797a. PMID 16480278.
- ↑ "Acute poisoning involving the pyrrolidinophenone-type designer drug 4'-methyl-alpha-pyrrolidinohexanophenone (MPHP)". Forensic Science International 208 (1–3): e20-5. May 2011. doi:10.1016/j.forsciint.2011.02.026. PMID 21444164.
- ↑ "Schedules of Controlled Substances: Temporary Placement of N-Ethylhexedrone, α-PHP, 4-MEAP, MPHP, PV8, and 4-Chloro-α-PVP in Schedule I". Drug Enforcement Administration. https://www.deadiversion.usdoj.gov/fed_regs/rules/2019/fr0501.htm.
- ↑ "23 nya ämnen kan klassas som narkotika eller hälsofarlig vara". http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2015/juni/23-nya-amnen-kan-klassas-som-narkotika-eller-halsofarlig-vara.
 |  |
